- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02980562
Comparison of Low Volume PEG-Asc and Lower Volume PEG-Asc With Bisacodyl
Comparison of a Split Dose Bowel Preparation With 2-L Polyethylene Glycol Plus Ascorbic Acid and 1-L Polyethylene Glycol Plus Ascorbic Acid and Bisacodyl Prior to Colonoscopy
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
- Study design A single center, randomized, comparative observer-blinded study was performed from May 2015 to September 2015 at the Department of Gastroenterology and Digestive Endoscopy at Korea University Anam Hospital (Seoul, Korea).
In total, 200 outpatients received lower volume 1-L PEG with ascorbic acid plus bisacodyl (1L-PEG/AB) or low volume 2-L PEG with ascorbic acid (2L-PEG/A) in a 1:1 ratio.
At the time of registration, subjects were randomly allocated to either group. They were randomized by a computer-generated list and were provided with written instructions. All patients provided written informed consent.
- Patients All patients between the ages of 20 and 75 years. Patients were excluded from the analysis if they had known or suspected gastrointestinal obstruction, Ileus, severe heart failure, uncontrolled hypertension (systolic pressure > 170 mmHg, diastolic pressure > 100 mmHg), severe constipation, clinically significant electrolyte abnormalities, any prior bowel resection, or significant gastroparesis.
- Bowel preparation In the 2L-PEG/A group, 1 L of PEG containing ascorbic acid was taken at 8:00 pm on the day before the colonoscopy, followed by an extra 500 mL of water. The second 1-L of PEG containing ascorbic acid was taken 4 h before the colonoscopy examination, with an additional 500 mL of water. Each liter of preparation and the extra 500 mL water had to be consumed within 2 h of the procedure.
The 1L-PEG/AB group received 10 mg bisacodyl at 9:00 pm on the day before the colonoscopy. Four hours before the colonoscopy examination, 1 L of PEG containing ascorbic acid was taken, followed by an additional 1 L of water. The preparation was completed 2 h before the examination. All colonoscopies were performed between 9 am and 1 pm.
- Assessment by endoscopists Colonoscopies were performed by two expert endoscopists who were blinded to the preparation regimen. These two endoscopists worked for more than 5 years at our institution.
Bowel cleansing was scored by the same endoscopist performing the colonoscopy. To assess the cleansing quality of the bowel preparations, the Boston Bowel Preparation Scale (BBPS) and the Aronchick Bowel Preparation Scale (ABPS) were used.
- Assessment of patient tolerability and adverse events Before the colonoscopy procedure, patients completed questionnaires about their symptoms associated with the preparations to assess tolerability. Patients were asked to assess the degree of abdominal fullness, abdominal pain, nausea, vomiting, sleep disturbances, and general discomfort using a 5-point scale (i.e., none, mild, moderate, severe, or very severe).
The palatability of the preparation was graded in 5 categories: very good, good, acceptable, disgusting, and bad.
- Sample size and statistical analysis A sample size of at least 89 patients group was required for each treatment group to detect a difference in treatment success of a 5% type-I error rate and 80% power for a two-tailed χ2 test. Our sample size was based on the results from a pilot study that was conducted in our hospital and included 35 patients in each group. It was estimated that the efficacy for excellent treatment success would be 49% with PEG-2L/A and 30% with PEG-1L/AB. Based on these data, we decided to collect 100 patients per treatment group for study.
Continuous variables were expressed as mean ± standard deviation (SD), and discontinuous variables were expressed as counts and percentages. SPSS 20.0 for Windows (SPSS Inc., Chicago, IL, US) was used for data entry and statistical analyses. For the analyses between the two treatment groups, Students t-test as appropriate was used to compare continuous variables and either the Chi-square or Fisher's exact test were used for categorical data. The p-values < 0.05 were considered statistically significant.
Study Type
Enrollment (Actual)
Phase
- Phase 3
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- All patients between the ages of 20 and 75 years who were scheduled to undergo colonoscopy
Exclusion Criteria:
- aged more than 75 years.
- known or suspected gastrointestinal obstruction, Ileus
- severe heart failure
- uncontrolled hypertension (systolic pressure > 170 mmHg, diastolic pressure > 100 mmHg)
- severe constipation
- clinically significant electrolyte abnormalities
- any prior bowel resection, or significant gastroparesis.
Study Plan
How is the study designed?
Design Details
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: SINGLE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
ACTIVE_COMPARATOR: 2L Polyethylene glycols-Asc
1 L of PEG containing ascorbic acid (PEG A) was taken at 8:00 pm on the day before the colonoscopy, followed by an extra 500 mL of water.
The second 1-L of PEG containing ascorbic acid was taken 4 h before the colonoscopy examination, with an additional 500 mL of water.
Each liter of preparation and the extra 500 mL water had to be consumed within 2 h of the procedure.
All colonoscopies were performed between 9 am and 1 pm.
|
(Split dose 2L PEG-Asc)
Other Names:
|
ACTIVE_COMPARATOR: 1L PEG-Asc plus bisacodyl
10 mg bisacodyl at 9:00 pm on the day before the colonoscopy.
Four hours before the colonoscopy examination, 1 L of PEG containing ascorbic acid was taken, followed by an additional 1 L of water.
The preparation was completed 2 h before the examination.
All colonoscopies were performed between 9 am and 1 pm.
|
(1L PEG-Asc plus bisacodyl)
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
The quality of the bowel preparation using preparation scale
Time Frame: 20 minutes
|
Preparation scale
|
20 minutes
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
The patient's tolerability
Time Frame: 30 minutes before the colonoscopy
|
Patients were asked with questionnaires about the symptoms
|
30 minutes before the colonoscopy
|
Collaborators and Investigators
Sponsor
Investigators
- Study Director: Yoon Tae Jeen, Division of Gastroenterology and Hepatology, Department of Internal Medicine, Institute of Gastrointestinal Medical Instrument Research, Korea University College of Medicine
- Principal Investigator: Seung Hun Kang, Division of Gastroenterology and Hepatology, Department of Internal Medicine, Institute of Gastrointestinal Medical Instrument Research, Korea University College of Medicine
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Primary Completion (ACTUAL)
Study Completion (ACTUAL)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ESTIMATE)
Study Record Updates
Last Update Posted (ESTIMATE)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- Korea University preparation
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Bowel Disease
-
Medtronic - MITGCompletedInflammatory Bowel Disease | Small Bowel DiseaseUnited States
-
Hull University Teaching Hospitals NHS TrustWellcome/EPSRC Centre for Interventional and Surgical Sciences, University...RecruitingInflammatory Bowel Disease 1United Kingdom
-
Centre Hospitalier Universitaire, AmiensFunding from DGOS (PHRC IR 2013 and PRME)CompletedPediatric Inflammatory Bowel DiseaseFrance
-
University of Wisconsin, MadisonTerminatedInflammatory Bowel Disease (IBD)United States
-
Cedars-Sinai Medical CenterUnknownPediatric Inflammatory Bowel Disease
-
University of British ColumbiaCompletedInflammatory Bowel Disease 11Canada
-
University of ChicagoTerminatedInflammatory Bowel Disease (IBD)United States
-
Assiut UniversityNot yet recruitingIBD-Inflammatory Bowel Disease
-
University of Wisconsin, MadisonCompletedInflammatory Bowel Disease (IBD)United States
-
Kyungpook National University HospitalDaegu Catholic University Medical Center; Yeungnam University Hospital; DongGuk...RecruitingIdiopathic Chronic Inflammatory Bowel DiseaseKorea, Republic of
Clinical Trials on Polyethylene Glycols
-
WellSpan HealthNeuraptive Therapeutics Inc.RecruitingInjury of Other Nerves at Wrist and Hand Level of Unspecified Arm, Initial EncounterUnited States
-
Aga Khan UniversityRecruitingHepatic EncephalopathyPakistan
-
Delta University for Science and TechnologyCompletedPhysical Therapy in Pediatric Functional ConstipationEgypt
-
University of AarhusQufora A/SRecruitingFunctional Constipation | Fecal Incontinence in ChildrenDenmark
-
Children's Memorial Health Institute, PolandMedical University of Bialystok; University of RzeszowUnknown
-
Peking Union Medical College HospitalRecruiting
-
Tomas Bata Hospital, Czech RepublicBrno University Hospital; Faculty Hospital Kralovske VinohradyCompleted
-
Zimmer BiometCompleted
-
University of PadovaCompletedHypothermia, Preterm Infants
-
Changhai HospitalUnknownAdenoma Detection Rate | Bowel Preparation ScaleChina